https://www.notiziariochimicofarmaceutico.it
The annual report of Alliance for Regenerative Medicine (ARM) shows that the advanced therapy area received grants spanning 20 billion dollars during 2020, used by industry for the rapid development of new products. The increase of investment in new cellular therapies was particularly significant (+160% compared to 2019). Furthermore, investment in gene therapies were more moderate, but still considerable (+73%). The ARM report highlights that advanced therapy area represents a thriving sector. In 2020, 14 companies operating in regenerative medicine, have been listed in stock market, with a related improvement of commercial performance of around 44%.